^
Association details:
Biomarker:POLE V411L
Cancer:Colorectal Cancer
Drug:Opdivo (nivolumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

526O - High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours

Published date:
09/20/2020
Excerpt:
Responses were observed in MMRp colorectal and endometrial cancers with P286R and V411L mutations….Nivolumab activity appears promising in edPOLE mutated MMRp advanced cancer pts...
Trial ID: